ZWIJNAARDE (Ghent), Belgium, August 20, 2019. MyCartis to spin out point-of-need diagnostics business in new company ANTELOPE Dx. New start-up raises 5,1 million EUR

An investment consortium, with RMM (Rudi Marien) and Saffelberg (Jos Sluys) as lead investors, has invested in the new spin-off Antelope Dx. Together with some high net worth individuals, they have invested 5,1 million EUR in the new diagnostic company that develops innovative technology and applications for point-of-care testing.

Read full article

ZWIJNAARDE (Ghent), Belgium, July 17, 2019. Today, MyCartis and XVIVO Perfusion AB announce a collaboration to engage in the development of a fast diagnostic tool to timely assess the quality of donated organs during ex-vivo perfusion. Such test can guide the transplant surgeon and team on the quality of an organ, the optimal timing of the surgery and the chances of a positive outcome for the recipient.

In a recent whitepaper, MyCartis demonstrated the successful application of interleukin-1β as an indicator for inflammation in lung organs during perfusion. With results generated within 20 minutes, this test meets the required turnaround time for real-time organ assessment as well as organ follow-up. MyCartis and XVIVO decided to expand the testing panel to also enable the quantitation of organ damage next to the degree of inflammation. Both phenomena are negative indicators for successful transplantation. In line with the inflammation test, an assay fit-for-purpose in real-time organ assessment will be developed to measure at least one additional biomarker in the perfusion fluid.

Read full article

13 december 2018, MyCartis announces the addition of a point-of-need testing technology, ANTELOPE Dx, to complement its immuno - assay technology offering.MyCartis continues to innovate in next generation immunodiagnostic technologies and as such it will engage in a novel point - of - need diagnostic solution named ANTELOPE Dx.

ANTELOPE Dx is an immuno - diagnostic platform in development, that aims to offer clinical lab performance with the ease - of - use of a pregnancy test at a consumer price tag.The technology originated from UGent, Belgium, under supervision of Professor Peter Bienstman, in the Photonics Research Group of Professor Roel Baets, with Jan - Willem Hoste as lead investigator.Jan - Willem Hoste will play a crucial role in the further development of the technology, the platform and the test menu.

Read full article

MyCartis has made significant progress in the development of a fast (<30min) immunoassay to objectively assess the fitness of a donor organ during perfusion as well as predict the post-surgery acceptance and survival. This is the first time that an assay meets the required analytical performance criteria required in this emerging field and is ideally suited for repeat (interval) testing during the organ perfusion process. These assay characteristics are made possible through a combination of DMAT® features as well as unique Evalution® platform concepts. When implemented, the transplant surgeon would get timely insight on the organ fitness and gain confidence in the successful outcome of this life-saving procedure.

Read full article

In August 2018, an extensive executive MyCartis team was present at 70th AACC exhibition in Chicago to discuss its Evalution® technology with interested strategic partners. This exhibition is worldwide the largest one covering all aspects of clinical chemistry, a community MyCartis is a proud part of.

"Making more donor organs available for successful transplantation is essential in order to shorten waiting times and reduce mortality rates on the transplant waiting list. Because of their unique capability of running very fast immunoassays, we approached MyCartis to work on an assay for the real-time and timely assessment of donor organs undergoing ex-vivo perfusion."

Prof.Dr. Andrew Fisher ,
Academic Director and Honorary Consultant Physician, Institute of Transplantation, Freeman Hospital
Newcastle Upon Tyne Hospitals NHS Foundation Trust

Endorsement of MyCartis’ ISO 13485 Certificate

The December ’17 TUV surveillance audit endorses MyCartis’ ISO 13485 Certificate of Compliance.

News archive

Meet us at KfG 2018

Visit us at the 14th edition of Knowledge for Growth, May 17 in Ghent Belgium, booth 67.

Hilde Windels, CEO of Mycartis will be present at JP Morgan Healthcare conference in San Francisco, 6-10 Jan 2019. The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

MyCartis moved to its new lab and office space

End of 2017 MyCartis moved to Bioscape, a newLife Science incubator in Ghent with state of the art labs and office space.

MyCartis is looking for a COO/CTO

Read more


AACC 2019

4 - 8 August 2019

Anaheim, CA USA